Logo image of DCPH

DECIPHERA PHARMACEUTICALS IN (DCPH) Stock Fundamental Analysis

NASDAQ:DCPH - Nasdaq - US24344T1016 - Common Stock - Currency: USD

25.59  +0.02 (+0.08%)

After market: 25.61 +0.02 (+0.08%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to DCPH. DCPH was compared to 572 industry peers in the Biotechnology industry. DCPH has a great financial health rating, but its profitability evaluates not so good. DCPH is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year DCPH has reported negative net income.
In the past year DCPH has reported a negative cash flow from operations.
DCPH had negative earnings in each of the past 5 years.
In the past 5 years DCPH always reported negative operating cash flow.
DCPH Yearly Net Income VS EBIT VS OCF VS FCFDCPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -100M -200M -300M

1.2 Ratios

The Return On Assets of DCPH (-45.24%) is comparable to the rest of the industry.
DCPH has a Return On Equity (-60.25%) which is in line with its industry peers.
Industry RankSector Rank
ROA -45.24%
ROE -60.25%
ROIC N/A
ROA(3y)-50.14%
ROA(5y)-44.56%
ROE(3y)-68.79%
ROE(5y)-58.11%
ROIC(3y)N/A
ROIC(5y)N/A
DCPH Yearly ROA, ROE, ROICDCPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20 -40 -60 -80

1.3 Margins

DCPH's Gross Margin of 96.95% is amongst the best of the industry. DCPH outperforms 97.91% of its industry peers.
DCPH's Gross Margin has been stable in the last couple of years.
DCPH does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 96.95%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.59%
GM growth 5YN/A
DCPH Yearly Profit, Operating, Gross MarginsDCPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -200 -400 -600 -800

More info and screens

7

2. Health

2.1 Basic Checks

DCPH does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, DCPH has more shares outstanding
DCPH has more shares outstanding than it did 5 years ago.
There is no outstanding debt for DCPH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
DCPH Yearly Shares OutstandingDCPH Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
DCPH Yearly Total Debt VS Total AssetsDCPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

2.2 Solvency

DCPH has an Altman-Z score of 7.32. This indicates that DCPH is financially healthy and has little risk of bankruptcy at the moment.
DCPH has a Altman-Z score of 7.32. This is amongst the best in the industry. DCPH outperforms 83.07% of its industry peers.
There is no outstanding debt for DCPH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 7.32
ROIC/WACCN/A
WACC8.89%
DCPH Yearly LT Debt VS Equity VS FCFDCPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M -200M 400M

2.3 Liquidity

DCPH has a Current Ratio of 4.19. This indicates that DCPH is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 4.19, DCPH is in line with its industry, outperforming 45.03% of the companies in the same industry.
A Quick Ratio of 3.94 indicates that DCPH has no problem at all paying its short term obligations.
DCPH has a Quick ratio (3.94) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.19
Quick Ratio 3.94
DCPH Yearly Current Assets VS Current LiabilitesDCPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 5.96% over the past year.
The Revenue has grown by 26.51% in the past year. This is a very strong growth!
DCPH shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 57.16% yearly.
EPS 1Y (TTM)5.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.33%
Revenue 1Y (TTM)26.51%
Revenue growth 3Y57.16%
Revenue growth 5YN/A
Sales Q2Q%27.22%

3.2 Future

Based on estimates for the next years, DCPH will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.21% on average per year.
Based on estimates for the next years, DCPH will show a very strong growth in Revenue. The Revenue will grow by 25.42% on average per year.
EPS Next Y5.08%
EPS Next 2Y14.35%
EPS Next 3Y20.37%
EPS Next 5Y18.21%
Revenue Next Year25.31%
Revenue Next 2Y26.97%
Revenue Next 3Y32.58%
Revenue Next 5Y25.42%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
DCPH Yearly Revenue VS EstimatesDCPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M 800M 1B
DCPH Yearly EPS VS EstimatesDCPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 -2 4 -4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for DCPH. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DCPH. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DCPH Price Earnings VS Forward Price EarningsDCPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DCPH Per share dataDCPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 3

4.3 Compensation for Growth

DCPH's earnings are expected to grow with 20.37% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.35%
EPS Next 3Y20.37%

More info and screens

0

5. Dividend

5.1 Amount

DCPH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DECIPHERA PHARMACEUTICALS IN

NASDAQ:DCPH (6/10/2024, 8:00:00 PM)

After market: 25.61 +0.02 (+0.08%)

25.59

+0.02 (+0.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-10 2024-05-10/bmo
Earnings (Next)08-07 2024-08-07/bmo
Inst Owners6.97%
Inst Owner Change0%
Ins Owners26.79%
Ins Owner Change0%
Market Cap2.21B
Analysts71.25
Price Target27.25 (6.49%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.41%
Min EPS beat(2)8.03%
Max EPS beat(2)8.79%
EPS beat(4)4
Avg EPS beat(4)8.32%
Min EPS beat(4)6.6%
Max EPS beat(4)9.87%
EPS beat(8)7
Avg EPS beat(8)5.71%
EPS beat(12)8
Avg EPS beat(12)3.61%
EPS beat(16)12
Avg EPS beat(16)5.04%
Revenue beat(2)1
Avg Revenue beat(2)-3.37%
Min Revenue beat(2)-9.86%
Max Revenue beat(2)3.11%
Revenue beat(4)3
Avg Revenue beat(4)1.42%
Min Revenue beat(4)-9.86%
Max Revenue beat(4)7.77%
Revenue beat(8)5
Avg Revenue beat(8)0.97%
Revenue beat(12)8
Avg Revenue beat(12)1.76%
Revenue beat(16)12
Avg Revenue beat(16)51.69%
PT rev (1m)1.26%
PT rev (3m)17.06%
EPS NQ rev (1m)9.43%
EPS NQ rev (3m)8.94%
EPS NY rev (1m)1.43%
EPS NY rev (3m)3.18%
Revenue NQ rev (1m)2.15%
Revenue NQ rev (3m)1.7%
Revenue NY rev (1m)0.68%
Revenue NY rev (3m)0.89%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 12.65
P/FCF N/A
P/OCF N/A
P/B 7
P/tB 7
EV/EBITDA N/A
EPS(TTM)-2.21
EYN/A
EPS(NY)-1.59
Fwd EYN/A
FCF(TTM)-1.76
FCFYN/A
OCF(TTM)-1.76
OCFYN/A
SpS2.02
BVpS3.65
TBVpS3.65
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -45.24%
ROE -60.25%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 96.95%
FCFM N/A
ROA(3y)-50.14%
ROA(5y)-44.56%
ROE(3y)-68.79%
ROE(5y)-58.11%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.59%
GM growth 5YN/A
F-Score4
Asset Turnover0.42
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 29.04%
Cap/Sales 0.32%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.19
Quick Ratio 3.94
Altman-Z 7.32
F-Score4
WACC8.89%
ROIC/WACCN/A
Cap/Depr(3y)87.89%
Cap/Depr(5y)217.78%
Cap/Sales(3y)2.44%
Cap/Sales(5y)7.94%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.33%
EPS Next Y5.08%
EPS Next 2Y14.35%
EPS Next 3Y20.37%
EPS Next 5Y18.21%
Revenue 1Y (TTM)26.51%
Revenue growth 3Y57.16%
Revenue growth 5YN/A
Sales Q2Q%27.22%
Revenue Next Year25.31%
Revenue Next 2Y26.97%
Revenue Next 3Y32.58%
Revenue Next 5Y25.42%
EBIT growth 1Y-9.23%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year5.52%
EBIT Next 3Y4.87%
EBIT Next 5YN/A
FCF growth 1Y33.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y32.37%
OCF growth 3YN/A
OCF growth 5YN/A